Cue Biopharma Inc (CUE)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

21 ERIE STREET CAMBRIDGE, MA 02139

Cue Biopharma, Inc. operates as a bio-technology company. The Company discovers and develops medicines for cancers and autoimmune diseases. Cue Biopharma focuses on design and clinical development of protein biologics, immunology, and immuno-oncology. Cue Biopharma serves customers in the State of Massachusetts.

Data as of 2020-07-04
Market Cap651.216 Million Shares Outstanding28.45 Million Avg 30-day Volume423.289 Thousand
P/E Ratio Dividend Yield EPS-1.61
Price/Sales222.006 Price cash flow ratio Price free cash flow ratio-24.5
Book Value1.59 Price to Tangible Book14.4 Alpha
Short Interest Ratio % Short Interest to Float R-squared
BETA 52-week High/Low31.69 / 6.54 Stddev
View SEC Filings from CUE instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 2 2 (0.13%)
13F Filers holding this stock: 76 28 (1.83%)
Aggregate 13F shares on 03/31/2020: 13.073 Million 9.777 Million
Aggregate 13F shares on 12/31/2019: 10.554 Million 7.217 Million
Percent change: 23.86% 35.47%
Funds creating new positions: 19 11
Funds Adding to an existing position: 23 9
Funds closing out their position: 6 2
Funds reducing their position: 16 3
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CUE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CUE BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

7.5 Thousand total shares from 2 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SIMON BARRY J. SEE REMARKS

  • Officer
  • Director
3,170,540 2020-07-08 1

DRISCOLL FREDERICK W

  • Director
0 2020-07-02 1

FLETCHER AARON G.L.

  • Director
6,712 2020-06-30 4

KIENER PETER A

0 2020-06-23 1

DIGIANDOMENICO ANTHONY

  • Director
281,509 2020-06-08 0

MORICH FRANK

  • Director
0 2020-05-11 2

SURI ANISH PRESIDENT AND CSO

  • Officer
34,558 2020-03-31 4

PIENTA KENNETH CHIEF MEDICAL OFFICER

  • Officer
0 2020-03-24 1

PASSERI DANIEL R CEO

  • Officer
  • Director
0 2020-02-05 1

SANDERCOCK COLIN SVP, GENERAL COUNSEL AND SEC

  • Officer
0 2020-02-05 1

MILLAR KERRI-ANN VP-FINANCE

  • Officer
0 2020-02-05 1

MCKNIGHT STEVEN L

  • Director
0 2020-01-06 1

GRAY CAMERON

  • Director
0 2020-01-02 1

MARLETT CHRISTOPHER A

  • Director
0 2020-01-02 4

MANCILLA BETHANY SVP AND CHIEF BUSINESS OFFICER

  • Officer
0 2019-03-06 0

DIGIANDOMENICO ANTHONY

DIGIANDOMENICO ANTHONY

  • Director
57,000 2018-12-28 0

CHAPARRO RODOLFO EVP, HEAD OF IMMUNOLOGY

  • Officer
0 2018-07-23 0

SEIDEL RONALD D. III EVP, HEAD OF R&D

  • Officer
0 2018-07-23 0

SCHUMAN GARY ALAN INTERIM CFO

  • Officer
66,750 2017-12-18 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

FLETCHER AARON G.L. - Director

2020-06-24 P 4,547 $24.64 a 155,499 167,319.00 direct

FLETCHER AARON G.L. - Director

2020-06-24 P 2,953 $25.24 a 158,452 167,319.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments